论文部分内容阅读
作者以改良式(Check 氏)方法测定了18例肝硬化病人血浆纤维结合蛋白(Fibronectin)活性。其平均滴定度为1:14.3,与我院测定134例正常对照者的平均滴度1:61.9相比,有显著统计学差异(p<0.01)。有报导指出血结纤维结合蛋白活性的下降与肝硬化病人肝脏枯否氏细胞功能受损有关,因此这类病人容易患内毒血症和败血症,从而导致肝细胞衰竭、休克或成人呼吸窘迫综合症。作者建议,使用纤维结合蛋白制剂治疗肝硬化病人可有助于预防这些严重并发症。
The authors used the modified (Check’s) method to determine the plasma fibronectin activity in 18 patients with cirrhosis. The average titer was 1: 14.3, which was significantly different from the average titer of 1: 61.9 in 134 normal controls in our hospital (p <0.01). It has been reported that the decrease in the activity of fibronectin is associated with impaired Hepatic dysfunction in cirrhotic patients and is therefore susceptible to endotoxemia and septicemia resulting in hepatocellular failure, shock or adult respiratory distress syndrome disease. The authors suggest that the use of fibronectin preparations to treat cirrhotic patients may help prevent these serious complications.